137 related articles for article (PubMed ID: 10807429)
1. A novel in vitro effect of the mucosal protective agent sofalcone--inhibition of chemotactic motility in Helicobacter pylori.
Yoshiyama H; Nakamura H; Okamoto T; Okita K; Nakazawa T
Aliment Pharmacol Ther; 2000 Apr; 14 Suppl 1():230-6. PubMed ID: 10807429
[TBL] [Abstract][Full Text] [Related]
2. The effect of sofalcone on indomethacin-induced gastric ulcers in a Helicobacter pylori-infected gnotobiotic murine model.
Kabir AM; Shimizu K; Aiba Y; Igarashi M; Takagi A; Koga Y
Aliment Pharmacol Ther; 2000 Apr; 14 Suppl 1():223-9. PubMed ID: 10807428
[TBL] [Abstract][Full Text] [Related]
3. Chemotaxis and motility of Helicobacter pylori in a viscous environment.
Yoshiyama H; Nakamura H; Kimoto M; Okita K; Nakazawa T
J Gastroenterol; 1999; 34 Suppl 11():18-23. PubMed ID: 10616760
[TBL] [Abstract][Full Text] [Related]
4. Effect of sofalcone on adherence, production of vacuolating toxin, and induction of interleukin-8 secretion by Helicobacter pylori.
Kamiya S; Osaki T; Kumada J; Yamaguchi H; Taguchi H
J Clin Gastroenterol; 1997; 25 Suppl 1():S172-8. PubMed ID: 9479645
[TBL] [Abstract][Full Text] [Related]
5. Urease plays an important role in the chemotactic motility of Helicobacter pylori in a viscous environment.
Nakamura H; Yoshiyama H; Takeuchi H; Mizote T; Okita K; Nakazawa T
Infect Immun; 1998 Oct; 66(10):4832-7. PubMed ID: 9746586
[TBL] [Abstract][Full Text] [Related]
6. Effects of anti-ulcer agents on antibiotic activity against Helicobacter pylori.
Sunairi M; Watanabe K; Suzuki T; Tanaka N; Kuwayama H; Nakajima M
Eur J Gastroenterol Hepatol; 1994 Dec; 6 Suppl 1():S121-4. PubMed ID: 7735928
[TBL] [Abstract][Full Text] [Related]
7. Gastric urease activity is inversely associated with the success of treatment for Helicobacter pylori: effect of sofalcone.
Suzuki M; Kitahora T; Nagahashi S; Suzuki H; Mori M; Hibi T; Ishii H
J Clin Gastroenterol; 1998; 27 Suppl 1():S183-6. PubMed ID: 9872519
[TBL] [Abstract][Full Text] [Related]
8. Sofalcone, a gastroprotective drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori: a randomized controlled comparative trial with cimetidine, an H2-receptor antagonist.
Higuchi K; Watanabe T; Tanigawa T; Tominaga K; Fujiwara Y; Arakawa T
J Gastroenterol Hepatol; 2010 May; 25 Suppl 1():S155-60. PubMed ID: 20586860
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effect of sofalcone on tumor necrosis factor-alpha and interleukin-1 beta production in human monocytes stimulated by Helicobacter pylori water extract.
Fujiwara Y; Higuchi K; Fukuda T; Watanabe T; Tominaga K; Arakawa T
Drugs Exp Clin Res; 2001; 27(3):103-6. PubMed ID: 11447767
[TBL] [Abstract][Full Text] [Related]
10. Sofalcone for treatment of Helicobacter pylori infection.
Fujioka T; Murakami K; Kubota T; Kodama R; Honda S; Nasu M
J Gastroenterol; 1996 Nov; 31 Suppl 9():56-8. PubMed ID: 8959521
[TBL] [Abstract][Full Text] [Related]
11. Chemotaxis of Helicobacter pylori: a urease-independent response.
Yoshiyama H; Mizote T; Nakamura H; Okita K; Nakazawa T
J Gastroenterol; 1998; 33 Suppl 10():1-5. PubMed ID: 9840007
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of gastric H+,K(+)-ATPase by the anti-ulcer agent, sofalcone.
Murakami S; Muramatsu M; Aihara H; Otomo S
Biochem Pharmacol; 1991 Sep; 42(7):1447-51. PubMed ID: 1656986
[TBL] [Abstract][Full Text] [Related]
13. Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin.
Isomoto H; Furusu H; Ohnita K; Wen CY; Inoue K; Kohno S
World J Gastroenterol; 2005 Mar; 11(11):1629-33. PubMed ID: 15786539
[TBL] [Abstract][Full Text] [Related]
14. Urease-independent chemotactic responses of Helicobacter pylori to urea, urease inhibitors, and sodium bicarbonate.
Mizote T; Yoshiyama H; Nakazawa T
Infect Immun; 1997 Apr; 65(4):1519-21. PubMed ID: 9119496
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with clarithromycin and sofalcone for eradication of Helicobacter pylori.
Kodama R; Fujioka T; Fujiyama K; Kawasaki H; Kubota T; Nasu M
Eur J Gastroenterol Hepatol; 1994 Dec; 6 Suppl 1():S125-8. PubMed ID: 7735929
[TBL] [Abstract][Full Text] [Related]
16. How Helicobacter pylori urease may affect external pH and influence growth and motility in the mucus environment: evidence from in-vitro studies.
Sidebotham RL; Worku ML; Karim QN; Dhir NK; Baron JH
Eur J Gastroenterol Hepatol; 2003 Apr; 15(4):395-401. PubMed ID: 12655260
[TBL] [Abstract][Full Text] [Related]
17. A supplemented soft agar chemotaxis assay demonstrates the Helicobacter pylori chemotactic response to zinc and nickel.
Sanders L; Andermann TM; Ottemann KM
Microbiology (Reading); 2013 Jan; 159(Pt 1):46-57. PubMed ID: 23139399
[TBL] [Abstract][Full Text] [Related]
18. [Sofalcone].
Fukuda Y; Shimoyama T
Nihon Rinsho; 2002 Feb; 60 Suppl 2():704-9. PubMed ID: 11979875
[No Abstract] [Full Text] [Related]
19. The susceptibility of Campylobacter pylori to antiulcer agents and antibiotics.
Nagate T; Numata K; Hanada K; Kondo I
J Clin Gastroenterol; 1990; 12 Suppl 1():S135-8. PubMed ID: 2212539
[TBL] [Abstract][Full Text] [Related]
20. Effects of sofalcone on necrotizing agents-induced gastric lesions and on endogenous prostaglandins in rats stomachs.
Saziki R; Arai I; Isobe Y; Hirose H; Aihara H
J Pharmacobiodyn; 1984 Nov; 7(11):791-7. PubMed ID: 6597872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
